The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most ...

Eli Lilly has morphed from a reliable pharma giant into a biotech powerhouse riding blockbuster success. Mounjaro and ...